Daré Bioscience to Present at the 2020 BIO Investor Forum Digital
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will present at the 2020 BIO Investor Forum, held digitally from October 13-15, 2020. Registered attendees can access the presentation on demand during the event. Following the forum, a recording will be available in the Investor Relations section of the company's website until October 29, 2020. Daré is focused on innovative women's health products, including Ovaprene®, Sildenafil Cream, DARE-BV1, and DARE-HRT1, enhancing treatment options across various areas including contraception and sexual health.
- None.
- None.
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the 2020 BIO Investor Forum, which will be held in a digital format October 13-15, 2020. The company presentation will be available on demand during the virtual event for all registered attendees.
Event registration is available at https://www.bio.org/events/bio-investor-forum-digital/registration-pricing.
Following the conclusion of the event, a recording of Ms. Johnson’s presentation will be available under “Events & Presentations" in the Investor Relations section of the Company's website at www.darebioscience.com until October 29, 2020.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s clinical-stage product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream,
Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website (https://darebioscience.gcs-web.com/) and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.
Contact:
Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
212-213-0006
Source: Daré Bioscience, Inc.
FAQ
When is the BIO Investor Forum presentation by Daré Bioscience?
How can I access the on-demand presentation from Daré Bioscience?
Until when will Daré Bioscience's presentation recording be available?
What innovative products is Daré Bioscience developing?
What is the focus area of Daré Bioscience?
